Dermapharm Holding SE: Dr. Jürgen Ott named new CMO

Grünwald, July 29, 2019 – The Supervisory Board of Dermapharm Holding SE (“Dermapharm”) has announced a change in the composition of the Management Board. The current Chief Marketing Officer Stefan Grieving will be leaving the company for health reasons on July 31, 2019. Dr. Jürgen Ott to succeed him as of October 1, 2019.

“We would like to thank Mr. Grieving for his longstanding commitment to Dermapharm. Over the past nine years, he has played a key role in shaping our company’s positive development and we have come to value him as a competent and loyal colleague. We wish him all the best for the future! In Dr. Jürgen Ott, we have now found a suitable successor as Chief Marketing Officer who, due to his extensive experience in the consumer goods and pharmaceutical industries, fits very well with Dermapharm,” explained Wilhelm Beier, Chairman of the Supervisory Board of Dermapharm Holding SE.

Dr. Jürgen Ott (51) has many years of experience in the marketing and sales sectors and will be responsible for both sales and marketing in his function as a member of the Dermapharm Management Board. His last position since 2010 was Head of Marketing Germany, since 2014 Head of Marketing & Sales Germany and from 2017 Regional Head Central Europe at Bionorica SE, a manufacturer of herbal pharmaceuticals. In particular, Dr. Ott brings valuable experience to the range of herbal products, which Dermapharm wants to further develop.

“I am very much looking forward to my tasks at Dermapharm,” explained Dr. Jürgen Ott. “Together with my colleagues, we will set important impulses for the optimal further development of the range of herbal products as part of our growth strategy and further expand Dermapharm’s position as a leading pharmaceutical manufacturer in selected markets.”